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Human L-ﬁcolin (P35, ﬁcolin-2) is synthesised in the liver and secreted into the bloodstream where it is one of the major pattern
recognition molecules of plasma/serum. Like other ﬁcolins, it consists of a collagen-like tail region linked to a ﬁbrinogen-related
globularhead;abasictripletsubunitarisesviaacollagen-liketriplehelix,andthisthenformshighermultimers(typicallya12-mer,
Mr 400K). Unlike other ﬁcolins, it has a complex set of binding sites arranged within an internal cleft enabling it to recognise a
varietyofmolecularpatternsincludingacetylatedsugarsandcertain1,3-β-glucans.Itisoneofthefewmoleculesknowntoactivate
the lectin pathway of complement. Recently, some disease association studies (at either the DNA or protein level) have implicated
L-ﬁcolin in innate immunity, where it might cooperate with pentraxins and collectins. Emerging lines of evidence point to a role
for L-ﬁcolin in respiratory immunity, where its aﬃnity for Pseudomonas aeruginosa could be signiﬁcant.
1.Introduction
1.1. Discovery. Ficolins were ﬁrst discovered as transform-
ing growth factor β-binding proteins present in porcine
uterus, characterised by the possession of both ﬁbrinogen-
related and collagen-like domains [1]. However, it was the
description of P35 as an opsonic, GlcNAc-speciﬁc lectin
that ﬁrst indicated that this family could be involved in
innateimmunityaspatternrecognitionmolecules[2].Avery
similar molecule named L- (for liver) ﬁcolin was indepen-
dently puriﬁed from human plasma on GlcNAc-Sepharose
[3]. Both resembled two other previously discovered plasma
proteins: EBP-37, which bound elastin [4], and hucolin,
which bound a corticosteroid derivative [5].
Despite some minor discrepancies in properties, it was
clear that the same protein was being isolated on diﬀerent
aﬃnity matrices, and the term L-ﬁcolin (or ﬁcolin-2) is now
used for this protein with a rather catholic taste in ligands. In
this, as in several other features, it resembles the intensively
studied mannan- (or mannose-) binding lectin [6], but by
deﬁnition a ﬁcolin has a ﬁbrinogen-like domain combined
with a collagen-like domain and is therefore not a collectin.
(Collectins combine a collagen-like domain with a C-type
lectin domain and resemble ﬁcolins and C1q in tertiary
structure.)
1.2. The Ficolin Family. Porcine ﬁcolins consist of two ho-
mologous molecules, designated ﬁcolin-α and -β. Although
ﬁrst discovered in uterine tissue, porcine ﬁcolin-α is more
abundant in liver and blood where two isoforms, “little
ﬁcolin” (Mr∼400 000) and “big ﬁcolin” (Mr∼800 000) were
described[7].Ficolin-β,witharound80%identitytoﬁcolin-
α, was found to be expressed mainly in neutrophils [8].
A similar situation exists in mice. Ficolin A is present
in liver and blood plasma, while ﬁcolin B (60% identical) is
expressed in bone marrow and spleen and is associated with
macrophages [9, 10].
These ﬁndings have prompted the generalisation that
ﬁcolins can be classiﬁed into soluble serum ﬁcolins and cell-
bound ﬁcolins whatever the species. This view is supported
by a similar dichotomy in the toad, Xenopus laevis [11]. The
relationships between ﬁcolins in the above species and others
have been reviewed in more detail by Matsushita [12]a n db y
Garred et al. 2010 [13].
1.3. Human Ficolins. Unlike pigs or mice, humans have three
ﬁcolins, all of which are present in the bloodstream: M-
ﬁcolin (monocyte ﬁcolin or ﬁcolin-1); L-ﬁcolin (liver ﬁcolin
or ﬁcolin-2); and H-ﬁcolin (Hakata antigen or ﬁcolin-3).
M- and L-ﬁcolin have approximately 80% identity in amino
acid sequence; H-ﬁcolin has only about 50% identity with2 Journal of Biomedicine and Biotechnology
Table 1: The human ﬁcolins.
M-ﬁcolin L-ﬁcolin H-ﬁcolin
Molecular size (subunit) 35K 35K 34K
Molecular size (native) 900K 420K 610K
Location Neutrophils, monocytes > serum liver; serum liver; bile; lung; serum
Chemical speciﬁcity Acetylated sugars
acetylated compounds;
LPS; 1,3-β-glucans;
lipoteichoic acids;
elastin; steroids
D-fucose > GlcNAc;
polysaccharide from
A.viridans
Microbial speciﬁcity E. coli; S. aureus; S. agalactiae
S. aureus; S. pneumoniae;
S. typhimurium; E. coli;
P .a e r u g i n o s a ;M .b o v i s ;
G. lamblia; T. cruzi;
A. fumigatus,
A. viridans; T. cruzi
Complement activation Yes Yes Yes
Opsonic activity ? Yes ?
Collagenase sensitivity Yes Yes No
the other two. M-ﬁcolin, predominantly found in monocytes
and granulocytes, is the homologue of murine ﬁcolin-B
and porcine ﬁcolin-β; L-ﬁcolin is the homologue of murine
ﬁcolin-A and porcine ﬁcolin-α [12].
The third human ﬁcolin, the Hakata antigen originally
identiﬁed and deﬁned by autoantibodies present in a small
minority of lupus patients, is synthesised in both liver
(secreted into bile as well as blood) and lung (and secreted
into the bronchi). It is the most abundant plasma ﬁcolin and
the most potent at activating complement in vitro [14, 15].
A comparison of the properties of the ﬁcolins is sum-
marised in Table 1. All three have the ability to activate
the lectin pathway of complement, an activity known to
be shared with just two collectins, mannan-binding lectin
(MBL) and CL-L1 [16, 17]. All three ﬁcolins seem to
recognise acetylated sugars like GlcNAc to some degree. L-
ﬁcolin (like MBL) appears to be a major pattern recognition
molecule in human plasma [18]. It has a uniquely complex
set of binding sites, potentially conferring the ability to
recognise and interact with a wide range of microorganisms
[19]. Recently, L-ﬁcolin has been the subject of several
disease association studies, providing evidence that L-ﬁcolin
complements MBL as an important component of innate
immunity in the circulation. The structure, properties and
function(s) of L-ﬁcolin form the remainder of this paper.
2.Genetics
The human L-ﬁcolin gene (FCN2) has been localised to
chromosome 9 (9q34) [20], like the M-ﬁcolin gene but in
contrast to the H-ﬁcolin gene located on chromosome 1.
The L-ﬁcolin gene has eight exons (Figure 1). The ﬁrst exon
encodes a signal sequence and the ﬁrst nine N-terminal
residues. Exons 2 and 3 encode a collagen-like region similar
to that found in collectins. The fourth exon encodes a link
or connecting region. Exons ﬁve to eight encode a domain
similar in structure to that of the C-terminal portion of the
human ﬁbrinogen β and γ chains that is characterized by the
conservation of 24 mainly hydrophobic amino acid residues.
The FCN2 gene is undoubtedly polymorphic. Hum-
melshoj et al. [21] ﬁrst described 5 polymorphisms in the
promotor region and 9 in the structural gene from a Danish
population. Compatible results were reported by Herpers
et al. [22], describing 10 single nucleotide polymorphisms
in 1888 Dutch blood donors. A later study compared ﬁve
diﬀerentethnicgroups;someethnic-speciﬁcpolymorphisms
were noted, but most were found in all populations [23].
Considerable linkage disequilibrium exists between pairs
of promoter and structural gene dimorphisms, complicating
theinvestigationoftherelationshipbetweenalleleexpression
and protein concentration, but such relationships certainly
exist. High concentrations appear to be associated with the
variant (minority) nucleotide at promoter position−4, while
low concentrations are associated with the variant allele at
position6424onexon8[24,25].Itisperhapssurprising,and
certainlyconfusing,thatthelattermutationisalsoassociated
with an increased lectin activity (GlcNAc binding). L-ﬁcolin
has several independent activities, however, associated with
a variety of binding sites (see below), and it is unknown if
other activities are aﬀected.
The single nucleotide polymorphisms implicated in
inﬂuencing protein concentration in one or more studies are
listed in Table 2. It is clear however that those mutations
have a very modest inﬂuence on average L-ﬁcolin values,
eachbeingassociatedwithlargeandoverlappingranges[25].
Although circulating L-ﬁcolin levels appear to be reasonably
stable in healthy individuals, it remains to be established
if nongenetic inﬂuences may have as great or greater an
eﬀect than the FCN2 genotype. For example, we found
that patients treated for haematological malignancies had
signiﬁcantly lower median serum L-ﬁcolin compared with
healthy controls [26]. Moreover, when studying babies with
sepsis, we have found large diﬀerences in some individuals
with time (unpublished).
Mostindividualspossessoneortwoofthemostcommon
ﬁve haplotypes, and Munthe-Fog et al. [25]h a v eh e l p f u l l y
stratiﬁed serum L-ﬁcolin concentration according to those
haplotypes. From this analysis, it is apparent that FCN2Journal of Biomedicine and Biotechnology 3
Cysteine-rich domain
Collagen-like domain
Neck region
Fibrinogen-like domain
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 Promoter
−986 −602 −557 −64 −4 +2488
+6359 +6424 +6442
Thr236Met Ala258Ser Ala264fs
Exon 1: signal peptide and start of N-terminal
domain
Exons 2-3: remainder of N-terminal domain
and collagen-like domain
Exon 4: linker region
Exons 5–8: ﬁbrinogen like domain
Figure 1: The human FCN2 gene. The positions of the major single nucleotide polymorphisms are shown. The mutation at +6442 leads to
ad e l e t i o n( f s= frameshift mutation).
Table 2: Potentially important polymorphisms in the FCN2 gene.
SNP no. Region and
position
Base
substitution
Amino acid
substitution
rs3124952 promoter −986 A>G—
rs3124953 promoter −602 G>A—
rs3811140 promoter −557 A>G—
rs28969369 promoter −64 A>C—
rs17514136 promoter −4A >G—
rs17549193 exon 8 +6359 C>T Thr236Met
rs7851696 exon 8 +6424 G>T Ala258Ser
genotype has little value in predicting protein concentration
in individuals. It has been suggested that the huge diﬀerence
in MBL concentration in general between groups with dif-
ferent MBL2 genotypes is woefully inadequate for predicting
serumMBLlevelsinindividualsandthatusingthatapproach
is unreliable for inferring diﬀerences in disease cohorts [27].
That limitation is even more true of FCN2 genotyping,
although immunogenetic studies may provide interesting
additional information to L-ﬁcolin protein measurement.
3. Structure
The primary structure is composed of 288 amino acids
forming a gene product of apparent Mr 35 000 after glycosy-
lation [2]. A short N-terminal region implicated in multimer
formation is followed by a series of 19 (Gly-X-Y) repeats
forming the collagen-like region or domain. This is attached
via a short linking sequence to a large globular domain with
a distinctive fold, homologous to the C-terminal domains
found in ﬁbrinogen chains. This ﬁbrinogen-like domain
occurs in several apparently unrelated proteins, including
tenascins, the acetylated sugar-binding tachylectins from a
horseshoe crab (Tachypleus tridentatus) and the sialic acid-
binding lectin from the slug, Limax ﬂavus [28].
The combination of ﬁbrinogen-like domain and
collagen-like region in L-ﬁcolin (and other ﬁcolins) permits
the gene product to form a basic subunit consisting a triple
helical tail and a trio of globular heads. This 3-dimensional
structure is often likened to a bowl of tulips and resembles
the shape of the complement component C1q and the
collectin family despite those other molecules not having
primary sequence homology with ﬁcolins or with each
other. The triplet subunits can then associate to form higher
multimers (Figure 2). The major form in plasma is believed
to be a tetramer of subunits (12-mer) with an apparent Mr
of approximately 400000 [10, 29].
L-ﬁcolinuniquelypossessesacomplexsetofbindingsites
constituting a recognition surface that can detect various
acetylated structures and neutral sugars in the context
of extended polysaccharides. This conclusion is based on
studies of its trimeric recombinant recognition domains
solved by X-ray crystallography [19, 30]. There is an outer
binding site (S1) close to the only calcium binding site.
This could be considered the ancestral binding site, as it is
homologous to that of the horseshoe crab tachylectin 5A as
well as that found in human H- and M-ﬁcolins. Surprisingly,
S1 is not responsible for recognition of acetylated sugars
unlike its counterpart in tachylectin 5A. Instead, L-ﬁcolin4 Journal of Biomedicine and Biotechnology
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Figure 2: L-ﬁcolin structure. The glycosylated gene product of Mr
35K forms a basic triplet subunit. The subunit can form higher
multimers, of which the 12-mer (4 × 3) is thought to be the most
abundant in serum. The inset (right) shows a typical western blot
after electrophoresis of L-ﬁcolin under nonreducing conditions.
possesses three inner binding sites (S2, S3, S4) that are
located on both sides of a cleft between the upper parts
of the protomers. It is S3 that is mainly responsible for
binding acetylated structures and also binds 1,3-β-glucans
with assistance from the minor site, S4. The innermost S2
has aﬃnity for galactose. The L-ﬁcolin recognition groove
with its contiguous subsites (S2–S4) is reminiscent of the
peptidoglycan binding proteins of invertebrates [19].
Theﬁcolins,collectins,andcomplementcomponentC1q
all have a similar 3-dimensional shape suited to function
as multivalent recognition molecules with increased aﬃnity
for ligands achieved by multiple protein-oligosaccharide
interactions. It is noteworthy that L-ﬁcolin possesses a semi-
open structure intermediate between the compact assembly
of C1q and the wide open arrangement of MBL which has
little interaction between the lectin domains and a buried
surface 8% the size of that of C1q [19].
The collagen-like region is responsible for the formation
of the helical tails of the molecule and also for functional
signalling. In particular, the lysine-57 residue is a key
component of the binding site for MBL-associated serine
proteases and also for calreticulin, a putative comple-
ment/collectin/ﬁcolin receptor on phagocytes [31].
4. Biological Properties
4.1. Biochemical Speciﬁcity. L-ﬁcolin was reported to bind to
mannan,mannan-Sepharose,andGlcNAc-BSAinacalcium-
dependent manner [2], whereas other workers described
calcium-independent binding to GlcNAc-Sepharose and
elution with GlcNAc [3]. L-ﬁcolin also bound to CNBr-
activated (but underivatized) Sepharose blocked with Tris.
Since L-ﬁcolin did not bind to mannan coupled to
“Emphase”(apolyacrylamidederivative)[32],itseemslikely
the aﬃnity chromatography was achieved with Sepharose
(i.e., polygalactose) not mannan; this interaction was possi-
bly mediated by binding site S2. The inconsistency regarding
calcium is to some extent explained by the observation that
L-ﬁcolin bound to GlcNAc-Sepharose or CysNAc-Sepharose
beads not only in the presence of calcium but also in the
absence of calcium at high NaCl concentrations [33]. Given
that X-ray crystallography has shown that the ancestral (S1)
calcium-associated binding site does not bind galactose or
acetylated sugars, it appears that the other binding sites are
inﬂuenced indirectly by their ionic environment.
It is clear that L-ﬁcolin binds not just to acetylated
sugars but also to nonsaccharide acetylated compounds [33].
Nevertheless, glycan array studies have established that L-
ﬁcolin does not bind to most acetylated oligosaccharides
found on mammalian glycoconjugates [34]. Rather, L-ﬁcolin
has complex recognition requirements and binding probably
requires the presence of two or more acetylated sugar groups
presented in an appropriate conformation. In another glycan
array study, L-ﬁcolin preferentially recognised disulphated
N-acetyllactosamineandtri-andtetrasaccharidescontaining
terminal galactose or N-acetylglucosamine and binding
was sensitive to the orientation of the bond between N-
acetyllactosamine and the adjacent saccharide [35].
L-ﬁcolin is the major 1,3-β-glucan-binding protein in
human plasma [18] and can bind to lipoteichoic acid [36].
Potentially, therefore, L-ﬁcolin could bind to a wide variety
of fungi and Gram-positive bacteria. L-ﬁcolin recognises
and binds to the viral envelope glycoproteins (E1 and E2)
of the hepatitis C virus and triggers the lectin pathway
of complement by binding to a virally infected human
hepatoma cell line [37].
L-ﬁcolin also appears to bind human DNA, suggesting a
mechanism for attaching to apoptotic or necrotic autologous
cells and thus promoting the removal of dead and moribund
cells and tissues [38]. It has already been mentioned that
L-ﬁcolin can bind to a protein, elastin [4], and a lipid [5].
Most signiﬁcantly, it can bind to the pentraxins, C-reactive
protein [39], pentraxin 3 (PTX3) [40], and serum amyloid P
component (J. D. Chalmers, unpublished).
4.2. Microbial Speciﬁcity. L-ﬁcolin has been found to bind
to the Gram-negative bacteria, Salmonella typhimurium
(Ra strain) [2], Escherichia coli [41], and Pseudomonas
aeruginosa [42], as well as the Gram-positive species, (cap-
sulated) Staphylococcus aureus and streptococci including the
pneumococcus [33, 43, 44]. All interactions were partially
sensitive to GlcNAc. L-ﬁcolin binding to the intracellular
bacterium Mycobacterium bovis has also been reported
[45]. Additionally, binding to Haemophilus inﬂuenzae and
Moraxella catarrhalis has been observed (J. D. Chalmers,
unpublished).
Binding of L-ﬁcolin to the protozoan causing Chagas’
disease, Trypanosoma cruzi, has been demonstrated [46]
and to the intestinal protozoan Giardia lamblia [47]. It
also binds the opportunistic fungal pathogen, Aspergillus
fumigatus[40].Thislastinteractioncanbepartiallyinhibited
by GlcNAc or Curdlan (a β-1,3-glucose polymer).
The L-ﬁcolin-mediated response to A. fumigatus is
enhanced by calcium-independent binding to PTX3 [40].
Similar synergy was observed between L-ﬁcolin and C-
reactive protein in response to P. aeruginosa [42]. These
appear to be impressive examples of how L-ﬁcolin can com-
bine with pentraxins to amplify antimicrobial recognition
and eﬀector mechanisms.
4.3. Complement Activation. L-ﬁcolin is one of the few mol-
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activation [48]. This arises after forming a complex with
MBL-associated serine proteases (MASP)-1, -2, and -3, of
which MASP-2 is crucial for complement activation. MASP-
2bindingtakesplaceatasiteonthecollagen-likeregion[31].
L-ﬁcolin-MASP-2 interaction leads to activation of the latter,
enabling it to cleave complement components C2 and C4 in
a manner similar to the C1q, r, s complex of the classical
pathway initiated by antigen-antibody formation. The roles
ofMASP-1anditsalternativelysplicedgeneproductMASP-3
are less clear, but evidence is accumulating that MASP-1 may
link complement to the coagulation system [49–53]a sw e l l
as collaborating with MASP-2 in the generation of the C3
convertase [54, 55]. MASP-3 is primarily found complexed
to H-ﬁcolin and appears to regulate complement activation
mediated by the latter [56].
The other activators of MASP-2 and hence the lectin
pathway are the other human ﬁcolins (M- and H-ﬁcolin)
and the collectins, MBL and CL-11/CL-K1 [16, 17]. In so far
as they have been directly compared, H-ﬁcolin emerged as
the most potent complement activator, at least as measured
in vitro by a particular C4 deposition assay [15]. L-ﬁcolin
and MBL were similar, but had only half the complement
activation capacity of H-ﬁcolin.
Unsurprisingly, L-ﬁcolin has been shown to possess
opsonic activity by enhancing phagocytosis of Salmonella
by human neutrophils [2]. It can also promote the phago-
cytosis of Pseudomonas aeruginosa [42]a n dStreptococcus
pneumoniae (J. D. Chalmers, unpublished). Although such
opsonisation may be mediated by complement activation, it
has also been suggested that L-ﬁcolin can opsonise bacteria
by binding calreticulin on phagocytes via its collagen-like
domain [31].
L-ﬁcolin can cooperate with pentraxins to opsonise
bacteria and initiate the lectin pathway, as was mentioned
earlier.
Two reports support the view that L-ﬁcolin can opsonise
autologous dead or dying cells and cellular debris [38, 57].
Kuraya et al. [57] concluded that L-ﬁcolin binds to apoptotic
cells and activates complement via the lectin pathway. Jensen
et al. [38], however, observed binding to necrotic but not
apoptotic cells, and only at supraphysiological concentra-
tions of ≥20μg/mL. High concentrations of L-ﬁcolin also
promoted the uptake of necrotic Jurkat cells by monocyte-
derived macrophages in a phagocytosis assay [38]. Many
molecules have been described as binding to apoptotic cells,
however, and we have no idea of their relative physiological
signiﬁcance in vivo.
5.L-FicolininHealth andDisease
5.1. L-Ficolin in Healthy Subjects. In healthy adult individu-
als, the distribution of serum L-ﬁcolin is perfectly Gaussian,
so the mean and median are exactly the same. That value has
generally been reported to be between 3 and 4μg/mL [58]
although more recently it has been determined at 5.4μg/mL
[25]. A complicating consideration is that puriﬁed L-ﬁcolin
is very labile (unlike in serum); if anything other than
a recently isolated preparation is used as a standard, the
values obtained from the calibration curve will be higher
than the true values. There is also scope for discrepancy
b e t w e e ni m m u n o a s s a y e dp r o t e i na n dam e a s u r e m e n tb a s e d
on activity. However, in general, we have found broadly
similar values to be obtained with either acetylated BSA or
anti-L-ﬁcolin antibody (clone GN4) as solid-phase capture
agent combined with the same labelled detection antibody
(clone GN5).
Most normal values fall within the range 1000 to
6000ng/mL, although occasionally much higher values are
detected. No value much below 1000ng/mL has been
detected in a healthy adult; therefore, absolute L-ﬁcolin
deﬁciency has not been shown to exist. From genetic
studies [21], a homozygous frameshift mutation in exon 8
(rs28357091; Ala264fs; FCN2-D) would be expected to give
total deﬁciency, but this has not yet been found.
Normal values are generally lower in antenatal (cord
blood) sera [3, 59–61] and correlate with gestational age,
at least until shortly before term [60]. Only one study
has investigated serum L-ﬁcolin throughout life [61]. The
highest values were found between 1 and 4 years of life
(median11300ng/mL),thendroppedduringlaterchildhood
(4–16 years, median 8660ng/mL) before reaching a stable
adult level (median 3370) after 16 years of age. Although
Sallenbach et al.’s values [61]w e r ei ng o o da g r e e m e n tw i t h
our and others’ adult data and reasonably close agreement
for antenatal data, their elevated values for later childhood
were at variance with our ﬁnding of similar-to-adult values
for such children [62].
Although no absolute deﬁciency of L-ﬁcolin has yet been
discovered, it seems possible that relative deﬁciency (“insuf-
ﬁciency”) deﬁned by low serum L-ﬁcolin ± immunogenetics
could contribute to disease susceptibility. Unfortunately, the
disease process itself (or treatment) might aﬀect circulating
L-ﬁcolin, as has been found for patients with haematological
malignancies [26], preeclampsia [63], and sepsis (D. C.
Kilpatrick, unpublished).
5.2. General Infections. L-ﬁcolin insuﬃciency was associated
with perinatal infections in preterm Polish babies [60].
In a cohort of over 1800 consecutive deliveries, the rate
of perinatal infections in babies with cord blood L-ﬁcolin
<1000ng/mL (the lowest 9%) was twice that of babies with
higher concentrations (13.7% versus 7.7%; P<0.01). This
relationship was not independent of gestational age and
birthweight, but suggests that L-ﬁcolin insuﬃciency could
be one of several factors that contribute to the adverse
consequences of prematurity and low birthweight [60].
Schlapback et al. [64], however, found no signiﬁcant
relationship between low cord blood L-ﬁcolin and sepsis
in 47 premature infants. This was despite ﬁnding sig-
niﬁcant relationships between low H-ﬁcolin and Gram-
positive sepsis and between low MBL and Gram-negative
sepsis. Incidentally, that study did conﬁrm correlations
between L-ﬁcolin concentration and both gestational age
and birthweight. It is possible that study was underpowered
for L-ﬁcolin: for Gram-negative sepsis, 47% (7/15) of the
patients had low (<1000ng/mL) L-ﬁcolin compared with
23% (22/94) of infection-free, matched controls (P<0.07)
[64].6 Journal of Biomedicine and Biotechnology
Uraemic patients have an increased susceptibility to
infection, and peritonitis is a common complication in
patients on continuous ambulatory peritoneal dialysis
(CAPD). The +6359 C>T variant in the FCN2 gene, causing
aT h r Met alteration and a concomitant decrease in lectin
activity, was found to be commoner in CAPD patients with
a history of staphylococcal peritonitis compared with CAPD
patients without such a history [65]. In the former, exit site
Staphylococcus aureus was also more prevalent [65].
Another clinical context of interest is that of chemother-
apy ± transplantation. MBL has been intensively studied in
thiscontextwithwildlydiﬀeringresults[66,67].Inourseries
of haematological malignancy patients who were rendered
severely neutropenic, entirely negative results were obtained
for both L-ﬁcolin and H-ﬁcolin [26].
However, the situation appears to be very diﬀerent in the
context of liver transplantation, where the recipient assumes
the phenotype of the donor. The variant FCN2 +6359 allele
was associated with a doubling of the bacterial infection
risk within the ﬁrst year following transplant, and the risk
was enhanced by coinheritance of MBL2 variant alleles [68].
Patients with one or more lectin pathway genetic variants
and infection had a much increased mortality rate which was
highly statistically signiﬁcant [68]. As well as those bacterial
infections causing sepsis and pneumonia, the normal (high
lectin activity) FCN2 +6359 was associated with protection
from cytomegalovirus after liver transplantation [69]. Again,
the combination of FCN2 and MBL2 risk alleles conferred a
particularly high degree of susceptibility.
5.3. Respiratory Infections. There is a strong theoretical
basis to believe L-ﬁcolin may be important in respiratory
infections. As discussed previously, L-ﬁcolin binds to and
opsonises a wide variety of important respiratory pathogens
(includingcapsulatedS.pneumoniae,S.aureus,P. aeruginosa,
H. inﬂuenzae and others). L-ﬁcolin, like MBL, has been
found in the inﬂamed lung (induced sputum and bron-
choalveolar lavage ﬂuid) in concentrations suﬃcient to cause
complement activation (J. D. Chalmers, unpublished).
In perhaps the ﬁrst disease association study involving
L-ﬁcolin, an association between L-ﬁcolin insuﬃciency and
recurrent respiratory infections in children was reported.
This relationship was particularly marked for patients with
coexisting allergic disorders (mostly rhinitis and/or asthma
with high IgE) [70]. This preliminary observation prompted
a fresh, prospective study on children aged 1 to 16 years
( m e a n8 . 9 )t oc o n ﬁ r mo rr e f u t et h ep r e v i o u sr e t r o s p e c t i v e
ﬁndings and to distinguish between infection and allergy
[62]. L-ﬁcolin insuﬃciency was indeed signiﬁcantly associ-
ated with asthma and/or allergic rhinitis in the context of
recurrent respiratory infections, but not with those allergic
disorders in the absence of infection or with recurrent
respiratory infections in the absence of allergy [62]. The
reason for this relationship is not clear, but it is possible that
L-ﬁcolin confers some protection from microorganisms that
exacerbate allergic inﬂammation in the lung.
Another research group examined FCN2 variants in a
birth cohort followed up for 4 years. Analysis based on con-
structed haplotypes yielded no relationship with recurrent
respiratoryinfection.NoserumL-ﬁcolinmeasurementswere
made [71].
Similarly negative immunogenetic results were obtained
in a study of invasive pneumococcal disease [72], but again
no serum L-ﬁcolin data were obtained.
There was a clear association between low serum L-
ﬁcolin and idiopathic bronchiectasis [73]. This has since
been conﬁrmed in a much larger series, and there is evidence
to suggest the basis could lie in protection from colonisation
with Pseudomonas aeruginosa [74]. Certainly, low serum
L-ﬁcolin in those patients identiﬁes a clinical phenotype
associated with more severe disease and therefore with
poorer quality of life.
5.4. Other Infectious Diseases. The distribution of FCN2
haplotypes in leprosy patients diﬀered signiﬁcantly from
healthy controls [75]. The authors interpreted their ﬁndings
as an indication that normal (relatively high) L-ﬁcolin
concentrations protect against M. leprae infections, but
serum L-ﬁcolin was not actually measured.
A comparison of mild and severe Plasmodium falciparum
malaria revealed that serum L-ﬁcolin concentration is high-
est during acute severe disease, but this diﬀerence was not
reﬂected in the distribution of the FCN2 haplotypes [76].
In contrast, the distribution of FCN2 haplotypes was
altered in cutaneous leishmaniasis patients when compared
with healthy controls [77]. Haplotypes expected to confer
normal concentrations of L-ﬁcolin were commoner in
the controls, but again serum L-ﬁcolin was not actually
measured.
5.5. Pregnancy Disorders. A small proportion of women who
had experienced recurrent miscarriage had serum L-ﬁcolin
values below the lower limit of normal [59]. These patients
were sampled at a single point in time, and a longitudinal
study would be required to determine if those low values
were stable. It would also be instructive to learn if and how
L-ﬁcolin varied during pregnancy in such patients.
According to Wang and coworkers [63], serum L-ﬁcolin
increases several-fold during normal pregnancy, although it
is not clear whether a direct comparison was made between
pregnantandnonpregnantsubjects.(Moreover,vandeGeijn
et al. [78] reported that serum L-ﬁcolin was not inﬂuenced
by pregnancy.) Certainly, Wang et al. found L-ﬁcolin levels to
be signiﬁcantly lower in preeclamptic pregnancies compared
with uncomplicated pregnancies of similar gestational age.
Postnatal placentae from preeclamptic pregnancies con-
tained higher concentrations of L-ﬁcolin in lysates, and
more intense immunohistochemical staining was observed
in syncytiotrophoblast. The co-expression of L-ﬁcolin and
Ras protein in preeclamptic syncytiotrophoblast was noted.
The authors interpret those observations as evidence of
consumption of L-ﬁcolin by apoptotic trophoblast causing
depletion in the circulation.
5.6. Miscellaneous Disorders. The distribution of FCN2 vari-
ants was found to be altered in poststreptococcal disease
[79]. A haplotype associated with low levels of L-ﬁcolinJournal of Biomedicine and Biotechnology 7
Table 3: Some disease associations of L-ﬁcolin insuﬃciency.
Disease Associated with Reference
Perinatal infections Low serum L-ﬁcolin [60]
Staphylococcal
peritonitis
FCN2 +6359 variant allele
(FCN2-B) [65]
Bacterial infections
following liver
transplantation
FCN2 +6359 variant allele
(FCN2-B) [68]
Childhood infections
combined with allergic
diseases
Low serum L-ﬁcolin [62, 70]
Idiopathic
bronchiectasis Low serum L-ﬁcolin [73, 74]
Preeclampsia Low serum L-ﬁcolin [63]
Chronic rheumatic heart
disease Promoter haplotype GGA [79]
was slightly but signiﬁcantly more frequent in patients
with chronic rheumatic heart disease (CRHD) compared
with healthy controls. Conversely, another haplotype was
commoner in controls than in either CRHD or rheumatic
fever patients. Since L-ﬁcolin can readily bind to Strepto-
coccus pyogenes and thereby activate complement [44], it is
conceivable that these immunogenetic diﬀerences are related
to an altered innate response.
A similar FCN2 investigation in Behcet’s disease was
essentially negative [80] as was the outcome of serum L-
ﬁcolin measurements in sarcoidosis [81]. Nevertheless there
was a trend towards lower circulating L-ﬁcolin in sarcoid
patients, in contrast to an increase noted for MBL.
Immunohistochemical evidence for L-ﬁcolin involve-
ment in IgA nephropathy has been found [82], but not in
renal allograft rejection [83].
The clearest associations of L-ﬁcolin insuﬃciency with
disease susceptibility are summarised in Table 3.
6. AnimalStudies
Animal work, though of indirect relevance to clinical
situations, often provides valuable supplementary evidence
concerning the function of human molecules. For example,
native (plasma-derived) and recombinant porcine ﬁcolin-α
was found to neutralise porcine reproductive and respiratory
virus (a major pathogen of swine) in vitro in a GlcNAc-
dependent manner [84]. However, variant alleles of ﬁcolin-
α were not associated with common infectious diseases
(pneumonia, enteritis, serositis, septicemia) at necropsy,
despite signiﬁcant associations with MBL-A, MBL-C, and
surfactant protein A [85]. Of more tenuous signiﬁcance was
the ﬁnding that a chimeric molecule combining the lectin
domain of MBL and the collagen-like region of L-ﬁcolin had
enhanced protective activity towards Ebola virus than either
of the parent molecules [86].
Ficolin-A-deﬁcientknockout micehavebeenestablished.
Survival of these mice after infection with Streptococcus
pneumoniae was reduced compared with that of wild-type
mice [87], but the phenotype of the knockout mice has not
been described in detail.
Human L-ﬁcolin cDNA has been cloned into an expres-
sion plasmid and used in a murine model of Salmonella
typhimurium infection [88]. Administration of L-ﬁcolin in
that form protected mice from a potentially lethal challenge
with Salmonella, with bacterial counts dramatically reduced
a week after infection compared with empty-vector-treated
controls. The recombinant L-ﬁcolin enhanced monocyte
phagocytosis of Salmonella in a dose-dependent manner
[88].
7. Conclusions
Human L-ﬁcolin is a unique plasma recognition molecule
with a broad speciﬁcity for microorganisms. It is capable
of complementing collectins (such as MBL) and pentraxins
in forming a battery of protective molecules constituting
the ﬁrst line of defence. Its functional activities are likely
to be mediated through the lectin pathway of complement
activation. Although clinical research involving L-ﬁcolin is
still in its infancy, evidence is emerging that insuﬃciency
of L-ﬁcolin might increase susceptibility to respiratory
infections. In particular, the possibility that L-ﬁcolin is a key
factor in protection from Pseudomonas aeruginosa warrants
further investigation.
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